Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
6 December 2004
The findings of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitor antidepressants are announced today. Attached is a letter which has been sent to health professionals and a questions and answers document.
›
Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants
›
Annex A - prescribing trends for SSRIs and related antidepressants
›
Annex B - list of search terms supplied to marketing authorisation holders
›
Annex C - Meta-analysis of paroxetine controlled trial data
›
Annex D - report of the Focus Group
› Proposed class warnings for product information
Download documents:
-
Annex B List of search terms supplied to MA holders (13Kb)
-
Annex A Prescribing Trends for SSRIs and related antidepressants (51Kb)
-
Proposed class warnings for product information (20Kb)
-
Safety of Selective Serotonin Reuptake Inhibitor antidepressants (70Kb)
-
Questions and Answers on findings of CSM expert working group on SSRIs (21Kb)
-
Report of the CSM expert working group on the safety of Selective Serotonin Reuptake Inhibitor antidepressants. (1013Kb)
-
Annex C Meta-analysis of paroxetine controlled trial data (58Kb)
-
Annex D Report of the Focus Group (57Kb)
